Sildenafil Citrate Sublingual Tablets, 100 mg

Urol.

Goldstein I, Lue TF, Padma-Nathan H,

How to Use Sildenafil Citrate 100mg Sublingual

Conclusions : 20 mg sublingual sildenafil is safe and effective in the treatment of erectile dysfunction. Sublingual administration has some advantages as it is not effected by food ingestion and quickly appears in the circulation. These advantages provide a faster onset of action with a lower dose when compared to oral sildenafil. Sublingual use of sildenafil may be more cost-effective and possibly provides a more predictable onset of action. Twenty mg of sublingual sildenafil shows a significantly higher efficacy than placebo in erectile dysfunction treatment.

Regional issues

65% of patients on sublingual sildenafil achieved satisfactory erections compared to 15% in the placebo group. The average onset of action for sublingual sildenafil was 15.5 minutes, versus 30 minutes for placebo. Sublingual sildenafil administration offers advantages including faster onset and lower required dosage compared to oral forms. The study aims to evaluate the safety and efficacy of sublingual sildenafil versus placebo in erectile dysfunction. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment J. Rosen RC, Steers WD, Wicker PA.

• Sildenafil citrate sublingual tablets are used for erectile dysfunction treatment.
• These tablets dissolve under the tongue for quick absorption.
• The recommended dose is typically 100mg per administration.
• Sublingual form bypasses digestive enzymes, leading to faster action.
• Use under medical supervision to avoid adverse effects.
• Do not exceed the prescribed dosage to prevent toxicity.
• Store in a cool, dry place away from sunlight.
• Not suitable for individuals on nitrate medications.
• Common side effects include headache and flushing.
• Consult a doctor before starting sildenafil therapy.
• Avoid alcohol when taking sublingual sildenafil tablets.

Development and evaluation of an abridged,

5-item ver- sion of the International

Sildenafil Citrate Sublingual Tablets IP 100mg Technical Specification:

In contrast, the endothelin antagonist bosentan has been associated with fluid retention and failure to improve symptoms of heart failure,101 and the prostacyclin analogue epoprostenol has been associated with increased mortality, especially in patients with coronary artery disease.102 Researchers in a second trial also evaluated the chronic effect of sildenafil on hemodynamics, as well as exercise dynamics. Guazzi and coworkers103 randomly assigned 46 male patients with NYHA functional class II or III heart failure (the presence of pulmonary hypertension was not necessary for inclusion) to receive sildenafil or placebo. At 3 and 6 months, the sildenafil-treated patients demonstrated a reduction in systolic pulmonary artery pressure, a reduction in ergoreflex effect on ventilation, an improvement in Vco2 production slope and Vo2max, and improvements in breathlessness score and flow-mediated vasodilation. The improvement in exercise efficiency was attributed to improved cardiopulmonary hemodynamics and improved sensitivity of the ergoventilatory reflex (a reflex that couples mechanoreceptors or chemoreceptors, or both, in exercising skeletal muscle to the control of ventilation), which, in turn, was possibly a result of improved skeletal muscle perfusion. The increase in cardiac output with sildenafil treatment has been attributed largely to an improvement in right ventricular function (which results from a decrease in pulmonary artery pressures) and to a decrease in systemic vascular resistance.

2. Affordable Pricing & Quality Assurance

Several observations support the concept that sildenafil has positive inotropic properties. In patients given inhaled nitric oxide with comparable reductions in the pulmonary vascular resistance, an increase in cardiac output was not noted in comparison to sildenafil.104 Moreover, Nagendran and associates105 confirmed a lack of phosphodiesterase type 5 in normal human right ventricular myocardium but were able to demonstrate its presence in hypertrophied right ventricular myocardium. In addition, they were able to show a positive inotropic effect with phosphodiesterase type 5 inhibition in this tissue. The mechanism of positive inotropy remains to be elucidated. Moreover, novel exciting data suggest that cGMP-dependent protein kinases are involved in the reversal of myocardial hypertrophy and subsequent improvement in ventricular function; thus, phosphodiesterase type 5 inhibitors may have a role in the treatment of ventricular hypertrophy and reverse remodeling. Index of Erectile Function (IIEF-5) as

a diagnostic tool for erectile dysfunction.

Packaging and Quality

In an animal model of ventricular hypertrophy induced by pressure overload, sildenafil administration prevented the development of ventricular hypertrophy and, in animals with established hypertrophy, reversed the hypertrophy. The postulated mechanisms are improved calcium handling, sildenafil-induced increase in cGMP concentration, and thus increase in cGMP-dependent protein kinase activity, which in turn appears to lead to a decrease in downstream hypertrophy signaling. At the same time, animals treated with sildenafil showed an improvement in ventricular systolic function.96,106 These findings are very encouraging and suggest that sil-denafil may successfully and safely decrease pulmonary artery pressures in patients with systolic heart failure and improve symptoms and exercise capacity even in patients with heart failure but without significant pulmonary hypertension.103 Larger prospective clinical trials are needed to confirm these findings and to evaluate the benefit of this agent on morbidity and mortality outcomes in patients with systolic heart failure. Moreover, the evidence that sildenafil may reverse hypertrophy suggests that it may have a role in the treatment of diastolic heart failure, as reviewed in detail in Chapter 48. Aspargo plans to file a new drug application with the FDA to support regulatory approval of ASP-001 for erectile dysfunction in the United States.

Regulatory Documentation Provided

Findings from a recent phase 1 trial show that ASP-001, an investigational sildenafil oral spray for patients with erectile dysfunction, achieved therapeutic levels at a significantly faster rate compared with traditional sildenafil citrate tablets (Viagra), announced Aspargo Labs, the developer of the formulation, in a news release.1 “The rapid and enhanced absorption profile demonstrated by ASP-001 in this phase 1 study highlight its potential to address key unmet needs in the treatment of erectile dysfunction,” said Steven Kaplan, MD, Chief Medical Officer at Aspargo Labs, director of the Men’s Wellness Program at the Mount Sinai Health System, and a professor at the Icahn School of Medicine at Mount Sinai.1 “Many patients struggle with the inconvenience and lack of spontaneity associated with planning ahead to take a tablet and the requirement to fast or time their dosing. An oral spray formulation that achieves therapeutic levels quickly could represent a significant advancement in patient-centric therapy. If approved, ASP-001 would be a welcome addition to the treatment landscape, offering patients and their partners a novel and practical option to enhance their sexual health and overall quality of life.” Overall, data from the phase 1 study showed that ASP-001 achieved initial absorption within 5 minutes of administration. At this time point, the average amount of medication in the bloodstream was 0.615 ng/mL with ASP-001, vs 0 ng/mL with sildenafil tablets. The average level of medication in the bloodstream via mean plasma concentrations remained higher for those who received ASP-001 vs those who received sildenafil tablets for the first 30 minutes following administration.